Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the U.S., Canada, and European markets. We show 28 historical shares outstanding datapoints in our EOLS shares outstanding history coverage, used to compute EOLS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EOLS market cap history over the course of time is important for investors
interested in comparing EOLS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EOLS versus a peer is one thing; comparing
EOLS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EOLS can fluctuate over the course of history.
With this page we aim to empower investors researching EOLS by allowing them to research the EOLS market cap history. |
Free EOLS Email Alerts:
Video: The Importance of Market Cap
